On September 27, 2024, Legend Biotech announced significant long-term survival data from the CARTITUDE-4 study, showing that CARVYKTI® reduces the risk of death by 45% in multiple myeloma patients compared to standard treatments. This makes CARVYKTI® the first cell therapy to improve overall survival in lenalidomide-refractory multiple myeloma as early as the second line of treatment.